Valproic Acid and Its Effects on HIV Latent Reservoirs
Status:
Unknown status
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine whether the co-administration of valproic acid
(Epival®), with highly active antiretroviral therapy (HAART) can reduce the size of HIV
latent reservoirs in infected CD4 cells.
Phase:
Phase 2
Details
Lead Sponsor:
McGill University Health Center McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborators:
Canadian Foundation for AIDS Research (CANFAR) CIHR Canadian HIV Trials Network